Patent: 7,838,646
✉ Email this page to a colleague
Summary for Patent: 7,838,646
Title: | Cystic fibrosis transmembrane conductance regulator gene mutations |
Abstract: | The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. The mutations include duplication of exons including duplication of exons 6b through 10. Methods of identifying if an individual contains the exons 6b through 10 duplication are provided as well as nucleic acid fragments that contain the junction site of the duplicated segment. The detection of additional mutations in the CFTR gene are also provided. |
Inventor(s): | Hantash; Feras (Dana Point, CA) |
Assignee: | Quest Diagnostics Investments Incorporated (Wilmington, DE) |
Application Number: | 11/506,453 |
Patent Claims: | see list of patent claims |
Details for Patent 7,838,646
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2025-08-18 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2025-08-18 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2025-08-18 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |